| Feb. 7, 2012 | H.I.G. Capital Opens Madrid Office |
| Feb. 1, 2012 | H.I.G. Capital Expands into Latin America with Rio de Janeiro Office |
| Jan. 3, 2012 | Novadaq Names MAQUET Cardiovascular Exclusive U.S. Distributor of CO2 Heart Laser Products |
| Dec. 22, 2011 | Novadaq to Present at the 14th Annual Needham Growth Conference |
| Dec. 7, 2011 | Tranzyme Pharma and Norgine Complete Enrollment in First of Two Pivotal Phase 3 Trials of Ulimorelin |
| Nov. 30, 2011 | Novadaq and KCI Sign Commercialization Agreements for the SPY System |
| Nov. 29, 2011 | Quinnova Pharmaceuticals, Inc. Launches New Website Targeted to Patients and Healthcare Providers |
| Nov. 8, 2011 | Tranzyme Pharma Announces the Extension of its Chemistry-Based Drug Discovery Collaboration with Bristol-Myers Squibb |
| Nov. 7, 2011 | Quinnova Pharmaceuticals, Inc. Announces the Launch of Neosalus® Lotion |
| Oct. 26, 2011 | OncoGenex Announces Publication of OGX-427 Pre-Clinical Data in Pancreatic Cancer |
| Oct. 24, 2011 | Novadaq to Release Q3-2011 Financial Results on November 4 – Conference Call to Follow |
| Oct. 20, 2011 | OncoGenex Pharmaceuticals Initiates an International, Randomized, Phase II Clinical Trial Evaluating OGX-427 in Advanced Bladder Cancer |
| Oct. 20, 2011 | Tranzyme Pharma Ranked Number 54 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500(TM) |
| Oct. 18, 2011 | Tranzyme Pharma Names Former Gilead Executive Franck Rousseau, M.D. Chief Medical Officer |
| Oct. 6, 2011 | Novadaq Reports 165 System Shipments During Third Quarter 2011 |
| Oct. 5, 2011 | Tranzyme Pharma Initiates Dosing in Phase 2b Trial of TZP-102 in Diabetic Patients With Gastroparesis |
| Sep. 29, 2011 | Apollo Endosurgery® Signs Agreement with Apollo Hospitals Group to Advance Incisionless Bariatric Surgery in India |
| Sep. 21, 2011 | A Phase III Clinical Trial Testing Long-Term Pain Management in Men With Metastatic Castrate-Resistant Prostate Cancer Is Open and Enrolling |
| Sep. 20, 2011 | Tranzyme Pharma Appoints George Abercrombie to Its Board of Directors |
| Sep. 19, 2011 | OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical |
| Sep. 12, 2011 | Tranzyme Pharma Announces Presentation of Additional Data for Its Oral Drug Candidate, TZP-102, at Annual Neurodiab Meeting in Porto, Portugal |
| Sep. 6, 2011 | OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals |
| Aug. 9, 2011 | David Moore Joins Tranzyme Pharma as Vice President, Commercial Operations |
| Jul. 25, 2011 | Novadaq to Release Q2-2011 Financial Results on August 4 – Conference Call to Follow |
| Jul. 20, 2011 | Tranzyme Pharma's Richard Eisenstadt Wins Triangle Business Journal CFO of the Year Award |
| Jun. 7, 2011 | Apollo Endosurgery Taps Michael Doty for CFO |
| Jun. 6, 2011 | Data from Pre-Clinical Studies Presented at the 2011 ASCO Annual Meeting Show Potential Combinability of Custirsen with MDV3100 and Hsp90 Inhibitors to Enhance Anti-Tumor Activity in Pr |
| May 24, 2011 | Novadaq Announces Appointment of G. Steven Burrill to Its Board of Directors |
| May 19, 2011 | Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting |
| May 18, 2011 | Novadaq to Present at BioFinance 2011 |
| May 18, 2011 | Novadaq Appoints David C. Martin Vice President, Business Development and Investor Relations |
| May 17, 2011 | OncoGenex to Present at the UBS Global Specialty Pharmaceuticals Conference |
| May 12, 2011 | Tranzyme Pharma Announces First Quarter 2011 Financial Results |
| May 12, 2011 | Novadaq Reports First Quarter 2011 Financial Results |
| May 11, 2011 | Novadaq Technologies Inc. Notice of Annual and Special Shareholder Meeting |
| May 10, 2011 | Tranzyme Pharma to Present Additional Phase 2 Data of Oral GI Motility Agent TZP-102 Showing Improvement of Debilitating Symptoms in Patients with Diabetic Gastroparesis |
| May 9, 2011 | OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2011 and Provides Update on Plans for the Phase 3 Prostate Cancer SATURN Clinical Trial |
| May 5, 2011 | Tranzyme Pharma Announces Partial Exercise of Over-Allotment Option for Initial Public Offering |
| May 3, 2011 | Tranzyme Pharma to Report First Quarter 2011 Financial Results |
| May 2, 2011 | OncoGenex to Webcast Discussion of First Quarter Financial Results on Monday, May 9, 2011 |
| Apr. 29, 2011 | Novadaq to Release Fiscal Q1-11 Financial Results on May 12 – Conference Call to Follow |
| Apr. 15, 2011 | New Class of Flexible Instruments from Apollo Endosurgery® Used for Endoluminal Removal of Gastric Tumor |
| Apr. 14, 2011 | OncoGenex Pharmaceuticals Announces Issuance of Key European Patent for OGX-427 |
| Apr. 4, 2011 | OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 |
| Apr. 1, 2011 | Tranzyme Pharma Announces Pricing of Its Initial Public Offering |
| Mar. 29, 2011 | OncoGenex to Present at the Needham & Company 10th Annual Healthcare Conference |
| Mar. 28, 2011 | Novadaq Reports Fiscal 2010 Full-Year and Fourth Quarter Financial Results |
| Mar. 25, 2011 | Novadaq Completes Private Placement Offering of Units |
| Mar. 22, 2011 | Novadaq to Present at the 10th Annual Needham Healthcare Conference |
| Mar. 21, 2011 | Novadaq to Release Fiscal 2010 Year-End and Q4-10 Financial Results on March 28 – Conference Call to Follow |
| Mar. 18, 2011 | Novadaq Announces Private Placement Offering of Units |
| Mar. 10, 2011 | OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2010 and Provides Update on Custirsen Clinical Development Program |
| Mar. 7, 2011 | OncoGenex to Webcast Discussion of Fourth Quarter and Full Year 2010 Financial Results on Thursday, March 10, 2011 |
| Mar. 4, 2011 | Tranzyme Pharma Appoints Financial and Pharmaceutical Leader Anne M. VanLent to its Board of Directors |
| Feb. 28, 2011 | OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference |
| Feb. 23, 2011 | Tranzyme Pharma and Norgine Initiate Dosing in Phase 3 Pivotal Study of Novel Intravenous GI Motility Drug Ulimorelin |
| Feb. 17, 2011 | OncoGenex Included in Fast Company Magazine's Top Ten "Most Innovative Companies" in the Biotech Industry |
| Feb. 8, 2011 | OncoGenex Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference |
| Feb. 2, 2011 | Novadaq Completes Purchase of TMR Business from PLC Systems |
| Jan. 19, 2011 | Two Laser Balloon “Live Cases” Shed New Light on Direct Visualization and PV Ablation |
| Jan. 4, 2011 | Novadaq to Present at January Investor Conferences |
| Jan. 1, 2011 | Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ Endoscopic Suturing System in Bariatric Repairs and GI Therapy |
| Dec. 20, 2010 | Quinnova Pharmaceuticals, Inc. Joins the Amneal Enterprises, LLC Alliance |
| Dec. 15, 2010 | Tranzyme Pharma Appoints Pharmaceutical Industry Veteran John H. Johnson as Chairman of its Board of Directors |
| Nov. 22, 2010 | OncoGenex Pharmaceuticals to Present at the Piper Jaffray 22nd Annual "Unplugged" Health Care Conference |
| Nov. 10, 2010 | Novadaq Reports Third Quarter 2010 Financial Results |
| Nov. 9, 2010 | NeurAxon, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference November 16, 2010 |
| Nov. 8, 2010 | Novadaq Enters Into Asset Purchase Agreement with PLC Systems for TMR |
| Nov. 8, 2010 | OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer |
| Nov. 4, 2010 | OncoGenex Reports Third Quarter Financial Results |
| Nov. 3, 2010 | Novadaq CEO to Present on SPY Imaging at November Investor Conferences |
| Nov. 1, 2010 | Apollo Endosurgery Completes First-in-Human Cases with New OverStitch™ Endoscopic Suturing System |
| Oct. 31, 2010 | NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine |
| Oct. 27, 2010 | Novadaq to Release Q3-10 Financial Results on November 10 – Conference Call to Follow |
| Oct. 26, 2010 | NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover |
| Oct. 22, 2010 | OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering |
| Oct. 21, 2010 | OncoGenex to Webcast Third Quarter Financial Results on Thursday, November 4, 2010 |
| Oct. 19, 2010 | OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering |
| Oct. 18, 2010 | OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering |
| Oct. 14, 2010 | NeurAxon Named One of Canada's Top 10™ Life Science Companies |
| Oct. 7, 2010 | Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors |
| Oct. 4, 2010 | OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum |
| Oct. 1, 2010 | Apollo Endosurgery Completes First-in-Human Cases with New OverStitch™ Endoscopic Suturing System |
| Sep. 30, 2010 | Teva and OncoGenex Announce Initiation of Second Phase 3 Trial of Custirsen in Men with Metastatic Prostate Cancer |
| Sep. 29, 2010 | NeurAxon Announces Closing of Convertible Debenture Financing |
| Sep. 28, 2010 | NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences |
| Sep. 27, 2010 | OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer |
| Sep. 22, 2010 | OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial |
| Sep. 15, 2010 | FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15 |
| Sep. 13, 2010 | Novadaq CEO to Present on SPY Imaging at September Investor Conferences |
| Sep. 7, 2010 | OncoGenex Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference and the UBS Global Life Sciences Conference |
| Sep. 1, 2010 | KCI's LifeCell™ Corporation and Novadaq Technologies Enter North American Sales and Marketing Agreement for Exclusive Distribution of SPY® Imaging System |
| Sep. 1, 2010 | Novadaq Signs North American Marketing and Sales Agreement with LifeCell |
| Aug. 25, 2010 | Tranzyme Pharma to Present Ulimorelin Data Showing Reduction in Daily Vomiting in Patients with Diabetic Gastroparesis |
| Aug. 23, 2010 | Novadaq Achieves Final Milestone in Intuitive Development Agreement |
| Aug. 17, 2010 | Joel I. Shalowitz, M.D., Appointed to Novadaq Board of Directors |
| Aug. 12, 2010 | Novadaq Reports Second Quarter 2010 Financial Results |
| Aug. 10, 2010 | OncoGenex Adds David V. Smith to the Board of Directors |
| Aug. 5, 2010 | OncoGenex Reports Second Quarter Financial Results |
| Aug. 04, 2010 | Gemin X Closes $8 Million Series E Financing |
| Jul. 29, 2010 | OncoGenex to Webcast Second Quarter Financial Results on Thursday, August 5, 2010 |
| Jul. 29, 2010 | NeurAxon, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference August 5, 2010 |
| Jul. 26, 2010 | Novadaq to Release Q2-10 Financial Results on August 12 – Conference Call to Follow |
| Jun. 29, 2010 | Tranzyme Pharma Announces Positive Results from Phase 2 Study of Oral TZP-102 (Ghrelin Agonist) in Patients with Diabetic Gastroparesis |
| Jun. 22, 2010 | Apollo Endosurgery recommended for $5 million Commercialization Award from the Cancer Prevention and Research Institute of Texas |
| Jun. 21, 2010 | OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer |
| Jun. 16, 2010 | Tranzyme Pharma and Norgine Sign License Agreement for Late-Stage Development Product, Ulimorelin (TZP-101), in Europe and Other Select Regions |
| Jun. 16, 2010 | New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism |
| Jun. 16, 2010 | New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism |
| Jun. 14, 2010 | HyperBranch Receives CE Mark for Adherus™ Spinal Sealant |
| Jun. 7, 2010 | OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX427 as a Treatment for Solid Tumors |
| Jun. 7, 2010 | Alder Biopharmaceuticals to Present at Two Upcoming Investor Conferences |
| Jun. 7, 2010 | Novadaq to Present on SPY Imaging at Needham Healthcare Conference |
| Jun. 6, 2010 | Alder Biopharmaceuticals' ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients |
| Jun. 3, 2010 | OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference |
| Jun. 2, 2010 | NeurAxon, Inc. to Present at 9th Annual Needham Healthcare Conference June 9, 2010 |
| May 18, 2010 | NeurAxon, Inc. to Make Multiple Presentations at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters |
| May 13, 2010 | OncoGenex Pharmaceuticals to Present at the 6th Annual Rodman and Renshaw Global Healthcare Conference |
| May 12, 2010 | Novadaq Reports First Quarter 2010 Financial Results |
| May 6, 2010 | OncoGenex Reports First Quarter Financial Results |
| May 01, 2010 | Apollo Endosurgery Introduces New "Flexible Surgery" Products at SAGES 2010 |
| Apr. 29, 2010 | OncoGenex to Webcast First Quarter Financial Results on May 6, 2010 |
| Apr. 28, 2010 | Novadaq to Release Q1-10 Financial Results on May 12 – Conference Call to Follow |
| Apr. 22, 2010 | Novadaq Technologies Notice of Annual Meeting |
| Apr. 20, 2010 | Gemin X Announces $16 Million Series D Financing |
| Apr. 8, 2010 | OncoGenex Pharmaceuticals Awarded BIOTECanada's Biotech Company of the Year Award |
| Mar. 30, 2010 | Novadaq Reports Fiscal 2009 Full-Year and Fourth Quarter Financial Results |
| Mar. 29, 2010 | Gemin X Completes Patient Enrollment in Phase 2 Clinical Study of Obatoclax for First-Line Treatment of Small Cell Lung Cancer |
| Mar. 25, 2010 | Data from OncoGenex Pharmaceuticals' Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting |
| Mar. 24, 2010 | OncoGenex Adds Biopharmaceutical Industry Veterans to the Board of Directors |
| Mar. 24, 2010 | Novadaq Receives Second Development Milestone Payment from Intuitive |
| Mar. 16, 2010 | Novadaq to Release Fiscal 2009 Year-End and Q4-09 Financial Results on March 30 – Conference Call to Follow |
| Mar. 15, 2010 | Peer-reviewed Research Elucidates Function of Hsp27; Supports OGX-427 Approach Targeting Cancer Treatment Resistance |
| Mar. 10, 2010 | Nuseal Brand Becomes Adherus |
| Mar. 8, 2010 | OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Provides Outlook for 2010 |
| Mar. 4, 2010 | OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 |
| Mar. 1, 2010 | Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX011, for the Treatment of Cancer |
| Feb. 25, 2010 | The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer |
| Feb. 22, 2010 | Novadaq Completes Private Placement Offering of Units |
| Feb. 17, 2010 | Novadaq Announces Private Placement Offering of Units |
| Jan. 11, 2010 | Novadaq to Present on SPY Imaging at Needham Conference |
| Jan. 11, 2010 | NeurAxon Awarded Grant from The Michael J. Fox Foundation to Research Novel Treatment Approach for Parkinson's Disease |
| Jan. 6, 2010 | OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding |
| Dec. 8, 2009 | Tranzyme Pharma Enters Into Strategic Drug Discovery Collaboration with Bristol-Myers Squibb |
| Nov. 10, 2009 | Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic |
| Oct. 28, 2009 | Safeguard Scientifics Leads $17.4 Million Series B Financing for Quinnova Pharmaceuticals |
| Oct. 13, 2009 | HyperBranch Receives CE Mark for NuSeal 30 Hernia Mesh Fixation Sealant |
| Apr. 14, 2009 | Quinnova Pharmaceuticals, Inc. Receives FDA Clearance on Neosalus™ Cream |
| Mar. 17, 2009 | HyperBranch Medical Technology, Inc Licenses OcuSeal Liquid Ocular Bandage to BD Medical - Ophthalmic Systems |
